Atrial Fibrillation Research Database

University of Campania Luigi Vanvitelli5,000 enrolled

Overview

All patients with atrial fibrillation who are treated with vitamin-k antagonists (warfarin, phenprocoumon) or non vitamin K oral anticoagulants (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) in real world settings will be recorded in this register. Within this register a characterization of patients and therapy (with regard to medication, dose and duration) will be done. On basis of defined clinical relevant end points the long-term efficacy and safety will be evaluated.

Study Type

OBSERVATIONAL

Enrollment

5,000

Conditions

Anticoagulants and Bleeding Disorders Atrial Fibrillation

Eligibility

Sex: ALLMin age: 18 YearsMax age: 110 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with atrial fibrillation * Indication for oral anticoagulant treatment Exclusion Criteria: * Missing Informed Consent Form * Missing Contact Informations for Follow up

Locations (1)

University of Campania "Luigi Vanvitelli"

Naples, Italy

RECRUITING

Outcomes

Primary Outcomes

Thromboembolic Events

Time frame: 1 year

Bleeding Events

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.